Benitec Ltd (BNIKF) 0.9400 $BNIKF
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Benitec Biopharma Completes AUD $31.5 million Private Placement
PR Newswire - Tue Apr 15, 7:30AM CDT
Benitec Biopharma Limited (ASX: BLT), today announced it has completed its previously announced private placement of up to approximately 29.4 million of the company's ordinary shares at a price of AUD $1.07 per ordinary share following a general meeting of its shareholders, who voted overwhelmingly in favor of approving the second tranche of the financing. As a result of receiving shareholder approval, Benitec will receive a total of approximately AUD $31.5 million to accelerate clinical development of its lead compound TT-034, a potential "single shot" treatment for hepatitis C. Proceeds will also be used to advance other programs in the company's pipeline, with a particular emphasis on the lung cancer, age-related macular degeneration, and hepatitis B programs.
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Benitec Biopharma Announces Private Placement of Ordinary Shares and Warrants
PR Newswire - Mon Feb 24, 6:30AM CST
Benitec Biopharma Limited (ASX: BLT), today announced it has completed a private placement of up to approximately 29.4 million of the company's ordinary shares at a price of AUD $1.07 per ordinary share, raising up to approximately AUD $31.5 million from international institutional investors who include U.S.-based RA Capital Management, Perceptive Advisors, Special Situations Funds and Sabby Management. In connection with the purchase of ordinary shares, Benitec agreed to issue the investors free attaching options to purchase up to an additional 13.2 million ordinary shares at an exercise price of AUD $1.26 per ordinary share, to expire in five-years.
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Marketwire - Tue Sep 17, 9:06AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"
, a subsidiary of Bio-Matrix Scientific Group Inc.
Regen BioPharma Inc licenses cancer gene silencing technology, expanding its cancer vaccine patent portfolio
M2 - Fri Aug 09, 4:39AM CDT
Biotechnology company Bio-Matrix Scientific Group Inc (OTCQB:BMSN) said on Thursday that it has entered into a license agreement for the development of vaccines using ddRNAi gene silencing technology.
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Marketwire - Thu Aug 08, 8:48AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
HCV clinical trial application submitted to Recombinant DNA Advisory Committee (RAC)
PR Newswire - Tue Apr 16, 5:30PM CDT
RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee (RAC) .
Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
PR Newswire - Mon Apr 15, 7:00PM CDT
RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the University of California, San Diego (UCSD), Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections (HCV). Benitec previously announced the selection of Duke Clinical Research Unit as the other site. TT-034 is being developed as a potential "one-shot-cure" for HCV.
Appointment of Mr. Kevin Buchi to Benitec Board
PR Newswire - Wed Apr 10, 9:23PM CDT
Benitec Biopharma Ltd (ASX: BLT), a biopharmaceutical company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), is very pleased to report that Mr. Kevin Buchi, CPA, has accepted an invitation to join the Company's Board of Directors.
Benitec Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical Trial
PR Newswire - Thu Mar 21, 6:00PM CDT
RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), Durham, North Carolina, USA as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential "one-shot-cure" for Hepatitis C (HCV).
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Benitec Biopharma Completes AUD $31.5 million Private Placement
PR Newswire - Tue Apr 15, 7:30AM CDT
Benitec Biopharma Limited (ASX: BLT), today announced it has completed its previously announced private placement of up to approximately 29.4 million of the company's ordinary shares at a price of AUD $1.07 per ordinary share following a general meeting of its shareholders, who voted overwhelmingly in favor of approving the second tranche of the financing. As a result of receiving shareholder approval, Benitec will receive a total of approximately AUD $31.5 million to accelerate clinical development of its lead compound TT-034, a potential "single shot" treatment for hepatitis C. Proceeds will also be used to advance other programs in the company's pipeline, with a particular emphasis on the lung cancer, age-related macular degeneration, and hepatitis B programs.
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Benitec Biopharma Announces Private Placement of Ordinary Shares and Warrants
PR Newswire - Mon Feb 24, 6:30AM CST
Benitec Biopharma Limited (ASX: BLT), today announced it has completed a private placement of up to approximately 29.4 million of the company's ordinary shares at a price of AUD $1.07 per ordinary share, raising up to approximately AUD $31.5 million from international institutional investors who include U.S.-based RA Capital Management, Perceptive Advisors, Special Situations Funds and Sabby Management. In connection with the purchase of ordinary shares, Benitec agreed to issue the investors free attaching options to purchase up to an additional 13.2 million ordinary shares at an exercise price of AUD $1.26 per ordinary share, to expire in five-years.
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Marketwire - Tue Sep 17, 9:06AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"
, a subsidiary of Bio-Matrix Scientific Group Inc. Regen BioPharma Inc licenses cancer gene silencing technology, expanding its cancer vaccine patent portfolio
M2 - Fri Aug 09, 4:39AM CDT
Biotechnology company Bio-Matrix Scientific Group Inc (OTCQB:BMSN) said on Thursday that it has entered into a license agreement for the development of vaccines using ddRNAi gene silencing technology.
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Marketwire - Thu Aug 08, 8:48AM CDT
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.
HCV clinical trial application submitted to Recombinant DNA Advisory Committee (RAC)
PR Newswire - Tue Apr 16, 5:30PM CDT
RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee (RAC) .
Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
PR Newswire - Mon Apr 15, 7:00PM CDT
RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the University of California, San Diego (UCSD), Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections (HCV). Benitec previously announced the selection of Duke Clinical Research Unit as the other site. TT-034 is being developed as a potential "one-shot-cure" for HCV.
Appointment of Mr. Kevin Buchi to Benitec Board
PR Newswire - Wed Apr 10, 9:23PM CDT
Benitec Biopharma Ltd (ASX: BLT), a biopharmaceutical company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), is very pleased to report that Mr. Kevin Buchi, CPA, has accepted an invitation to join the Company's Board of Directors.
Benitec Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical Trial
PR Newswire - Thu Mar 21, 6:00PM CDT
RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), Durham, North Carolina, USA as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential "one-shot-cure" for Hepatitis C (HCV).
